Riskpilot← Back to searchSign inGet full accessUroinvest AB
ABActiveOrg 5591191654Årsringsgatan 43General medical practice activities · NACE 8621Est. 20171 employees
Revenue 2024
SEK 355K
+9% vs 2023
EBITDA margin
26.9%
-66% vs 2023
Equity ratio
43.4%
Financial strength
Net profit 2024
SEK 51K
-78% vs 2023
| Revenue | SEK 355K | +9% |
| EBITDA | SEK 95K | -66% |
| Net profit | SEK 51K | -78% |
| Total assets | SEK 353K | -21% |
| Equity | SEK 153K | -49% |
| Employees | 1 | — |
Legal name
Uroinvest AB
Org number
5591191654
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
12 juli 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva sjukvårds- och läkartjänster samt därmed förenlig verksamhet. Bolaget skall även bedriva handel med värdepapper samt uthyrning av personal inom vård och omsorg samt därmed anslutande och närliggande verksamhet.
Address
Årsringsgatan 43
Email
john.akerlund@me.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 60 | 35 | 43 | 325 | 355 |
| Staff expenses | — | — | — | −1 | −16 |
| EBITDA | 38 | 16 | 0 | 280 | 95 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 38 | 16 | 0 | 280 | 95 |
| Net financials | — | — | 0 | 9 | −6 |
| Profit before tax | 37 | 16 | 0 | 289 | 89 |
| Tax | −8 | −3 | — | −59 | −38 |
| Net profit | 29 | 13 | 0 | 229 | 51 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 126 | 100 | 88 | 445 | 353 |
| Equity | 95 | 73 | 73 | 302 | 153 |
| Long-term debt | 5 | 10 | 10 | 10 | 29 |
| Short-term debt | 25 | 18 | 5 | 133 | 170 |
| Total debt | 30 | 28 | 14 | 143 | 200 |
EBITDA margin
26.9%
This company
15.8%
Market median
+70% vs market
20202024
Equity ratio
43.4%
This company
38.2%
Market median
+14% vs market
20202024
Return on equity
33.1%
This company
18.4%
Market median
+80% vs market
20202024
Net profit margin
14.3%
This company
8.1%
Market median
+77% vs market
20202024
Asset turnover
1.01×
This company
1.12×
Market median
+10% vs market
20202024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Uroinvest AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Ronald Åkerlund | Board of Directors | 0 companies |
| Eva Sofia Petronella Berglund | Deputy Board Member | 0 companies |